Findings

What do systematic reviews say?

27 questions · 27 findings · 2 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 7.4%GRADE not reported 0 · 0%Very low 7 · 25.9%Low 3 · 11.1%Moderate 9 · 33.3%High 6 · 22.2%

Summary of findings 2: PLD alone vs other conventional chemotherapy

Progression‐free survival · recurrent platinum‐resistant EOC

It is very uncertain whether summary of findings 2: PLD alone changes progression‐free survival (PFS) compared with other conventional chemotherapy (very low certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.94 [0.85, 1.04]
4 studies · 1803 participants
Very low

Intervention not reported

PFS¹ · women with newly diagnosed EOC (stage Ic to IV)

The intervention showed no clear difference in PFS¹ (high certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer 2013 · Cochrane Headline outcomes only
HR 1.01 [0.85, 1.19]
1 study · 820 participants
High

Intervention not reported

OS² · women with newly diagnosed EOC (stage Ic to IV)

The intervention showed no clear difference in OS² (high certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer 2013 · Cochrane Headline outcomes only
HR 0.94 [0.78, 1.13]
1 study · 820 participants
High

Intervention not reported

Anaemia (grade 3/4) · women with newly diagnosed EOC (stage Ic to IV)

The intervention leads to higher anaemia (grade 3/4) (high certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer 2013 · Cochrane Headline outcomes only
RR 2.74 [1.54, 4.88]
1 study · 803 participants
High

Intervention not reported

Thrombocytopenia (grade 3/4) · women with newly diagnosed EOC (stage Ic to IV)

The intervention leads to higher thrombocytopenia (grade 3/4) (high certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer 2013 · Cochrane Headline outcomes only
RR 8.09 [3.93, 16.67]
1 study · 803 participants
High

Intervention not reported

Alopecia (grade 2) · women with newly diagnosed EOC (stage Ic to IV)

The intervention leads to lower alopecia (grade 2) (high certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer 2013 · Cochrane Headline outcomes only
RR 0.09 [0.06, 0.14]
1 study · 803 participants
High

Intervention not reported

Neuropathy (grade 3/4) · women with newly diagnosed EOC (stage Ic to IV)

The intervention leads to lower neuropathy (grade 3/4) (high certainty).

1 finding from 1 review

Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer 2013 · Cochrane Headline outcomes only
RR 0.09 [0.01, 0.66]
1 study · 803 participants
High